UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 21, 2011
Biogen Idec Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
|
Delaware
(State or other jurisdiction
of incorporation)
|
|
0-19311
(Commission
file number)
|
|
33-0112644
(IRS Employer
Identification No.) |
| |
|
|
|
133 Boston Post Road, Weston, Massachusetts
(Address of principal executive offices)
|
|
02493
(Zip Code) |
Registrant’s telephone number, including area code: (781) 464-2000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
|
|
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On January 21, 2011, Biogen Idec Inc. issued a press release announcing that the European
Medicines Agency’s Committee for Medicinal Products for Human Use has issued a negative opinion
recommending against approval of FAMPYRA® (prolonged-release fampridine 10 mg tablets)
to improve walking ability in adult patients with multiple sclerosis in the European Union.
A copy of the press release is filed as Exhibit 99.1 and is incorporated herein by reference.
|
|
|
| Item 9.01 |
|
Financial Statements and Exhibits. |
The exhibits listed on the Exhibit Index immediately preceding such exhibits are filed as part
of this Current Report on Form 8-K.